MX2025004635A - Sal y forma cristalina de derivado heterociclico inhibidor, y metodo de preparacion y uso de las mismas - Google Patents

Sal y forma cristalina de derivado heterociclico inhibidor, y metodo de preparacion y uso de las mismas

Info

Publication number
MX2025004635A
MX2025004635A MX2025004635A MX2025004635A MX2025004635A MX 2025004635 A MX2025004635 A MX 2025004635A MX 2025004635 A MX2025004635 A MX 2025004635A MX 2025004635 A MX2025004635 A MX 2025004635A MX 2025004635 A MX2025004635 A MX 2025004635A
Authority
MX
Mexico
Prior art keywords
salt
crystal form
preparation
method therefor
heterocyclic derivative
Prior art date
Application number
MX2025004635A
Other languages
English (en)
Inventor
Xiaolan Zhan
Yuanyuan Li
Linsong Guo
Original Assignee
Shanghai Hansoh Biomedical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Shanghai Hansoh Biomedical Co Ltd
Publication of MX2025004635A publication Critical patent/MX2025004635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a una sal y a una forma cristalina de un derivado heterocíclico inhibidor, así como a un método de preparación de las mismas y al uso de las mismas; en particular, la presente invención se refiere a una sal y a una forma cristalina del compuesto representado por la fórmula general (I), a un método de preparación, a una composición farmacéutica que contiene una cantidad terapéuticamente eficaz de la sal y/o de la forma cristalina, y a su uso como inhibidor en el tratamiento de cánceres, en donde la definición de cada sustituyente en la fórmula general (I) es como se define en la descripción. (Ver Fórmula (I)).
MX2025004635A 2022-10-21 2025-04-21 Sal y forma cristalina de derivado heterociclico inhibidor, y metodo de preparacion y uso de las mismas MX2025004635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211299364 2022-10-21
PCT/CN2023/125513 WO2024083204A1 (zh) 2022-10-21 2023-10-20 杂环类衍生物抑制剂的盐、晶型及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2025004635A true MX2025004635A (es) 2025-06-02

Family

ID=90737004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025004635A MX2025004635A (es) 2022-10-21 2025-04-21 Sal y forma cristalina de derivado heterociclico inhibidor, y metodo de preparacion y uso de las mismas

Country Status (9)

Country Link
US (1) US20260151378A1 (es)
EP (1) EP4606802A1 (es)
JP (1) JP2025535427A (es)
KR (1) KR20250088625A (es)
CN (1) CN120019055A (es)
AU (1) AU2023362099A1 (es)
MX (1) MX2025004635A (es)
TW (1) TW202426443A (es)
WO (1) WO2024083204A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867783B (zh) * 2021-04-23 2026-08-07 康百达（四川）生物医药科技有限公司 吡啶衍生物及其在医药上的应用
WO2025218780A1 (zh) * 2024-04-19 2025-10-23 成都赜灵生物医药科技有限公司 Parp抑制剂并杂环类氘代化合物的晶型及其制备方法和用途
TW202606766A (zh) * 2024-06-28 2026-02-16 大陸商上海翰森生物醫藥科技有限公司 哌啶烯類化合物聯合用藥在製備治療癌症的藥物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
CN116143776A (zh) * 2021-11-22 2023-05-23 南京圣和药业股份有限公司 Parp1抑制剂及其应用
CN116535401A (zh) * 2022-01-25 2023-08-04 南京圣和药业股份有限公司 新的parp1抑制剂及其应用

Also Published As

Publication number Publication date
JP2025535427A (ja) 2025-10-24
TW202426443A (zh) 2024-07-01
AU2023362099A1 (en) 2025-06-05
WO2024083204A1 (zh) 2024-04-25
KR20250088625A (ko) 2025-06-17
CN120019055A (zh) 2025-05-16
EP4606802A1 (en) 2025-08-27
US20260151378A1 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
MX2023012054A (es) Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
EP4537900A3 (en) Compounds for inhibiting nlrp3 and uses thereof
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2025004385A (es) Derivado heterociclico inhibidor que contiene nitrogeno, metodo de preparacion para el mismo y uso del mismo
ZA202306437B (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
WO2024046512A3 (zh) 含氮大环类化合物及其制备方法和医药用途
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2024008008A (es) Derivado triciclico inhibidor, metodo de preparacion de este y aplicacion de este.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2025002452A (es) Serie de compuestos heterociclicos puenteados que contienen nitrogeno y metodo de preparacion de los mismos
MX2025006152A (es) Inhibidor polipeptidico, metodo de preparacion del mismo y uso del mismo
CR20240352A (es) Compuestos de uracilo sustituidos por n3 como inhibidores de trpa1
ZA202400823B (en) Inhibitors of transglutaminases
MX2025009098A (es) Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos
ZA202400821B (en) Inhibitors of transglutaminases
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
WO2024151638A3 (en) Compounds for fgfrs inhibitors
CR20250290A (es) Inhibidores de prmt5-mta
MX2025009982A (es) Sal de antagonista derivado que contiene anillo aromatico, metodo de preparacion del mismo y aplicacion del mismo